Effect of Dihydropyridine Calcium Channel Blocker on Mortality of Hypertension Patients With Moderate-Severe Pulmonary Acute Respiratory Distress Syndrome: A Multicenter Retrospective Observational Cohort Study

OBJECTIVES: The aim was to evaluate the effect of dihydropyridine calcium channel blocker on the prognosis for moderate-severe pulmonary acute respiratory distress syndrome in hypertension patients.

DESIGN: A retrospective, observational, multicenter cohort study.

SETTING: A total of 307 patients without propensity score matching and 186 adult inpatients with propensity score matching diagnosed with hypertension and moderate-severe pulmonary acute respiratory distress syndrome in five teaching hospitals in Jiangsu province, China, from December 2015 to December 2020 were enrolled.

PATIENTS: A total of 307 patients without propensity score matching and 186 patients with propensity score matching diagnosed with hypertension and moderate-severe pulmonary acute respiratory distress syndrome were included in the final analysis.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Demographic characteristics and clinical characteristics were recorded. The propensity score matching method was used to eliminate the difference between group with dihydropyridine calcium channel blocker and group without dihydropyridine calcium channel blocker. The primary outcome was in-hospital mortality. We used univariate and multivariate regression analyses for both patients with or without propensity score matching to assess the effect of these variables on mortality. In the subset of 186 patients with propensity score matching, in-hospital mortality was 53.2%. Inpatient mortality was significantly higher in patients treated with dihydropyridine calcium channel blocker than in those not treated with dihydropyridine calcium channel blocker of patients without propensity score matching (65.4% vs 40.4%; p < 0.01). Multivariate analysis for patients without propensity score matching showed that dihydropyridine calcium channel blocker (hazard ratio, 1.954; 95% CI, 1.415–2.699), lactate dehydrogenase greater than or equal to 600 U/L (hazard ratio, 3.809; 95% CI, 2.106–4.531), and lactate greater than or equal to 2 mmol/L (hazard ratio, 1.454; 95% CI, 1.041–2.029) were independently associated with in-hospital mortality. Based on univariate analysis for patients with propensity score matching, dihydropyridine calcium channel blocker (hazard ratio, 2.021; 95% CI, 1.333–3.064), lactate dehydrogenase greater than or equal to 600 U/L (hazard ratio, 4.379; 95% CI, 2.642–7.257), and lactate greater than or equal to 2 mmol/L (hazard ratio, 2.461; 95% CI, 1.534–3.951) were independently associated with in-hospital mortality. In contrast, patients not treated with dihydropyridine calcium channel blocker had a significant survival advantage over those treated with dihydropyridine calcium channel blocker in both patients without or
with propensity score matching \( (p < 0.001; p = 0.001 \text{ by Kaplan-Meier analysis}) \).

**CONCLUSIONS:** Dihydropyridine calcium channel blocker, lactate dehydrogenase greater than or equal to 600 U/L, and lactate greater than or equal to 2 mmol/L at admission were independent risk factors for patients with hypertension and moderate-severe pulmonary acute respiratory distress syndrome.

**KEY WORDS:** acute respiratory distress syndrome; dihydropyridine calcium channel blocker; hypertension; mortality

Despite decades of increased attention to acute respiratory distress syndrome (ARDS), the morbidity and mortality of ARDS remain alarmingly high (1–3). With the aging of the population, the number of hypertensive patients with ARDS is increasing year by year. Patients with pulmonary hypertension who progress to ARDS have a higher mortality (4, 5).

A study from our group revealed that dihydropyridine calcium channel blocker (DCCB) aggravated acute hypoxia-induced pulmonary hypertension via activation of Ca\(^{2+}\)-sensing receptor (CaSR) in pulmonary artery smooth muscle cells (PASMCs) (6, 7). Increased intracellular Ca\(^{2+}\) fluxes during the activation of CaSR also played an important role in the contract of PASMC. Activation of CaSR is also related to a variety of functional outputs including cell proliferation, differentiation, and inflammation (8). Pulmonary hypertension is a common complication of ARDS (4). Severe ARDS will progress to pulmonary hypertension which plays a major role in the physiopathology of ARDS and is associated with an increased risk of mortality (9).

DCCB is commonly used as antihypertension medicine in China. However, no more than 5% of patients with pulmonary artery hypertension benefit from calcium channel blocker (CCB) in a long-term treatment (10). Evidence showed that DCCB further exacerbated pulmonary hypertension and increased right ventricular systolic blood pressure, leading to right ventricular hypertrophy (11, 12). CCB-induced neurohormonal sympathetic activation and sustained CCB-generated nitric oxide production could cause inflammation and tissue destruction (13). Patients with pulmonary hypertension treated with CCB for an extended period were prone to develop CCB-related peripheral edema, which could reduce the patient compliance (14). CCBs have also been reported to suppress the functions of T cells and macrophages (15).

Therefore, it is necessary to detect whether DCCB could affect the prognosis of patients with hypertension combined with ARDS. Here, we conducted a retrospective cohort analysis of the multicenter to demonstrate the effect of DCCB on mortality of hypertensive patients with ARDS.

**MATERIALS AND METHODS**

**Design, Setting, and Study Population**

This retrospective study included all 376 adult inpatients (≥ 18 yr old) with a diagnosis of moderate-severe pulmonary ARDS and hypertension admitted to five teaching hospitals (The First Affiliated Hospital of Soochow University, Changshu No. 2 People’s Hospital, Lianyungang Municipal Oriental Hospital, Suzhou Ninth Hospital Affiliated to Soochow University, and The First People’s Hospital of Kunshan) from December 2015 to December 2020 (16, 17). Both physician and investigators reviewed chest radiographs in agreement for the diagnosis of ARDS. We excluded the patients 1) who were immunosuppressed or had cancer, 2) who had hypertensive heart disease or (congestive) heart failure at admission, 3) who died or were discharged within 24 hours of receiving a diagnosis of ARDS, and 4) who lack data. Data of 307 patients were collected. A 1:1 propensity score matching (PSM) was used to match measured baseline characteristics of populations with DCCB treatment to comparator populations. Eventually, 186 patients were included in this study (Fig. S1, http://links.lww.com/CCX/A748). Based on the degree of hypoxemia, three mutually exclusive categories of ARDS were identified according to the Berlin definition: mild \( (200 \text{ mm Hg} < \text{Pao}_2/\text{Fio}_2 \leq 300 \text{ mm Hg}) \), moderate \( (100 \text{ mm Hg} < \text{Pao}_2/\text{Fio}_2 \leq 200 \text{ mm Hg}) \), and severe \( (\text{Pao}_2/\text{Fio}_2 \leq 100 \text{ mm Hg}) \) (16). Patients with risk factors of pneumonia or aspiration of gastric contents were categorized as pulmonary ARDS. Patients were categorized as hypertension grade I (140–159/90–99 mm Hg) and hypertension grade II (≥ 160/≥ 100 mm Hg) based on their highest mean blood pressure in a 4-week period (18, 19). DCCB therapy was defined as at least one kind of DCCB medication for more than 3 months. The regular dose of DCCB included in our study is felodipine...
2.5 or 5 or 10 mg, amlodipine 5 or 10 mg, or nifedipine 30 or 60 mg. Mechanical ventilation strategies for patients were low-protective ventilation as supported by the ARDS Network trial (20). Spontaneous breathing trials and daily sedation interruptions were tried to eventually achieve unassisted breathing (21). This study was approved by the Committee for the Ethical Review of Research at The First Affiliated Hospital of Soochow University (IRB-2019050) and was conducted in accordance with institutional guidelines and the Declaration of Helsinki.

Data Collection

Demographic characteristics (age and gender) and clinical characteristics (comorbidities, laboratory findings, disease severity scores, treatment, complications, and outcomes) were recorded. Clinical data and chest radiographs are independently reviewed by two physicians to determine diagnostic accuracy. Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores were calculated based on component variables during the first 24 hours after admission (22, 23).

Patients were followed up until discharge from hospital or death, whichever came first. The primary outcome of our study was defined as in-hospital mortality.

Statistical Analysis

Continuous data with a normal distribution are presented as mean ± SD. If the continuous data are skewed, they are presented as median (interquartile range [IQR]). Frequency data are presented as proportions. According to the history of antihypertensive treatment, the patients were divided into with DCCB and without DCCB groups. A 1:1 PSM was used to reduce the selection bias of the two groups of baseline characteristics of populations with DCCB treatment to comparator populations. Propensity scores were calculated using Cox regression with the DCCB treatment cohort as the dependent variable and the following confounders initiation as independent variables: age, gender, smoke, alcohol, coronary artery disease, diabetes mellitus, Pao₂/Fio₂ ratio, albumin, lactate dehydrogenase (LDH), SOFA score, hemoglobin, and mechanical ventilation. C-statistics was used to evaluate the validity of PSM matching. For group without PSM, comparisons of continuous variables were made using Wilcoxon rank-sum and chi-square by cohort, whereas in the matched data, Wilcoxon signed-rank and McNemar or Stuart-Maxwell tests for marginal homogeneity were used to compare baseline characteristics for continuous variables and proportions, respectively (Table 1).

Univariate Cox regression models were used to identify independent risk factors for in-hospital observed mortality. Variables with \( p \) value of less than 0.2 (Table 2) in the univariate analysis were included in the multivariate model (Table 3). Multivariate regression model was performed to estimate the hazard ratio (HR) and 95% confidence interval (CI) to analyze the independent prognostic factors associated with mortality in hospitalized patients with hypertension and ARDS. Survival curves were plotted using the Kaplan-Meier method using the log-rank test and comparing both patients with and without DCCB treatment before and after PSM (Fig. 1). Data were analyzed using SPSS 25.0 (IBM, Chicago, IL). Excel 2016 (Microsoft) was used to prestatistical plot charts. A two-tailed \( p \) value of less than 0.05 was considered statistically significant.

RESULTS

Patients

Overall registry patient numbers and flow are shown in Figure S1 (http://links.lww.com/CCX/A748). Of the 376 patients diagnosed with hypertension and moderate-severe pulmonary ARDS, 12 patients were immunosuppressed or had cancer, 12 patients died within 24 hours of receiving the diagnosis of ARDS or had incomplete data, and 45 patients had hypertensive heart disease without (congestive) heart failure at admission were excluded. After matched by 1:1 PSM score, the final study included a total of 186 patients. As shown in Table 1, baseline characteristics of populations with PSM showed no evidence of a difference as confirmed by small standardized differences across DCCB treatment comparisons. Further, C-statistics was 0.74 for PSM.

In the univariate Cox regression model of group without PSM, gender, alcohol intake, with DCCB, LDH greater than or equal to 600 U/L, and lactate greater than or equal to 2 mmol/L were significantly associated with mortality (Table 3): with DCCB (HR, 1.954; 95% CI, 1.415–2.699; \( p < 0.001 \)), LDH greater than or equal to 600 U/L (HR, 3.089; 95% CI, 2.106–4.531; \( p < 0.001 \)), and lactate greater than or equal to 2
TABLE 1.
Comparison of Demographics and Clinicopathologic Characteristics of Unmatched and Matched Hospitalized Moderate-Severe Direct Acute Respiratory Distress Syndrome Patients With Hypertension With or Without the Dihydropyridine Calcium Channel Blocker Therapy

| Factors | Pre Matched | Post Matched |
|---------|-------------|--------------|
|         | Without DCCB (N = 151) | With DCCB (N = 156) | p | Without DCCB (N = 93) | With DCCB (N = 93) | p |
| Male, %, n (%) | 109 (72.2) | 127 (81.4) | 0.06 | 73 (78) | 75 (81) | 0.03 |
| Age, median (interquartile ranges) | 74.0 (65.0–82.0) | 74.5 (67.0–79.0) | 0.63 | 74.0 (66.0–78.0) | 75.0 (67.0–81.0) | 0.18 |
| Smoke, n (%) | 96 (63.6) | 92 (59.0) | 0.41 | 56 (60) | 63 (68) | 0.80 |
| Alcohol, n (%) | 60 (39.7) | 73 (46.8) | 0.21 | 44 (47) | 43 (46) | 0.02 |
| Hypertension grade, n (%) | 0.78 | 1.00 |
| I | 124 (82.1) | 129 (85.4) | – | 80 (86.0) | 79 (85) | – |
| II | 27 (17.2) | 26 (17.2) | – | 13 (14.0) | 14 (15.0) | – |
| Pre-existing comorbidity, n (%) | | | | | | |
| Coronary artery disease | 30 (19.9) | 31 (19.9) | 1.00 | 16 (17) | 21 (23) | 0.56 |
| Diabetes mellitus | 31 (19.9) | 31 (19.9) | 0.83 | 24 (26) | 22 (24) | 0.03 |
| Laboratory findings | | | | | | |
| Pac/Fio₂ ratio, median (interquartile ranges) | 112.0 (83.0–160.0) | 120.0 (95.0–160.0) | 0.83 | 115.0 (83.0–161.0) | 127.0 (95.2–157.6) | 1.00 |
| Categories of acute respiratory distress syndrome, n (%) | 0.74 | 0.03 |
| Moderate | 98 (64.9) | 104 (66.7) | – | 65 (70) | 63 (68) | – |
| Severe | 53 (35.1) | 52 (33.3) | – | 28 (30) | 30 (32) | – |
| WBC, median (interquartile ranges) | 9.7 (8.2–12.6) | 9.5 (6.9–13.5) | 0.54 | 9.7 (8.2–13.3) | 9.5 (7.9–13.5) | 0.73 |
| Hemoglobin, median (interquartile ranges) | 108.0 (89.0–119.0) | 114.0 (95.0–131.0) | < 0.01a | 107.0 (91.0–120.0) | 106.0 (91.0–120.0) | 0.97 |
| Platelets, median (interquartile ranges) | 130.0 (98.0–193.0) | 137.0 (71.0–198.0) | 0.6 | 140.0 (98.0–193.0) | 166.0 (114.0–213.0) | 0.09 |
| Albumin, median (interquartile ranges) | 31.8 (29.0–35.0) | 30.1 (26.8–33.3) | < 0.01a | 30.8 (27.0–35.0) | 30.1 (26.0–33.6) | 0.57 |
| Creatinine, median (interquartile ranges) | 88.8 (53.0–121.0) | 86.0 (60.0–110.5) | 0.79 | 88.8 (54.0–109.0) | 91.0 (57.0–123.0) | 0.47 |
| Blood urea nitrogen, median (interquartile ranges) | 11.7 (8.1–17.0) | 11.0 (8.2–17.0) | 0.83 | 12.4 (8.3–17.0) | 10.9 (8.1–16.6) | 0.13 |
| Lactate dehydrogenase, median (interquartile ranges) | 389.0 (278.0–561.0) | 302.5 (239.0–491.0) | 0.03a | 412.0 (288.0–561.0) | 306.0 (239.0–491.0) | 0.30 |
| Lactate, median (interquartile ranges) | 1.9 (1.6–2.9) | 2.1 (1.5–2.7) | 0.89 | 2.0 (1.6–2.8) | 2.1 (1.5–2.7) | 0.66 |
| C-reactive protein, median (interquartile ranges) | 103.0 (35.0–151.6) | 109.0 (35.0–195.0) | 0.42 | 105.0 (35.0–215.0) | 109.0 (35.0–151.6) | 0.40 |
| Procalcitonin, median (interquartile ranges) | 0.7 (0.3–5.7) | 0.9 (0.4–3.3) | 0.34 | 0.8 (0.3–6.4) | 0.8 (0.4–2.9) | 0.19 |

(Continued)
### TABLE 1. (Continued).
**Comparison of Demographics and Clinicopathologic Characteristics of Unmatched and Matched Hospitalized Moderate-Severe Direct Acute Respiratory Distress Syndrome Patients With Hypertension With or Without the Dihydropyridine Calcium Channel Blocker Therapy**

| Factors                                                                 | Pre Matched                                                                 | Post Matched                                                                 | p     |
|------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|-------|
|                                                                        | Without DCCB (N = 151)                                                   | With DCCB (N = 156)                                                        |       |
|                                                                        | Acute Physiology and Chronic Health Evaluation II score, median (IQR)     | Acute Physiology and Chronic Health Evaluation II score, median (IQR)     |       |
|                                                                        | 9.0 (7.0–13.0)                                                           | 9.0 (7.0–12.0)                                                             | 0.96  |
|                                                                        | 9.0 (7.0–13.0)                                                           | 9.0 (7.0–12.0)                                                             | 0.67  |
|                                                                        | Sequential Organ Failure Assessment score, median (IQR)                   | Sequential Organ Failure Assessment score, median (IQR)                   | 0.03a |
|                                                                        | 2.5 (2.0–4.0)                                                            | 3.0 (2.0–6.0)                                                              |       |
|                                                                        | 2.0 (2.0–4.0)                                                            | 3.0 (2.0–6.0)                                                              | 0.05  |
| Outcomes                                                               | Mechanical ventilation, n (%)                                            | Mechanical ventilation, n (%)                                             |       |
|                                                                        | 115 (76.2)                                                               | 130 (83.3)                                                                 | 0.12  |
|                                                                        | 115 (76.2)                                                               | 130 (83.3)                                                                 |       |
|                                                                        | Duration of ventilation, median (IQR)                                    | Duration of ventilation, median (IQR)                                    | 0.33  |
|                                                                        | 9.0 (2.0–20.0)                                                           | 11.0 (4.0–17.0)                                                            |       |
|                                                                        | 9.0 (2.0–20.0)                                                           | 11.0 (4.0–17.0)                                                            |       |
|                                                                        | Shock, n (%)                                                              | Shock, n (%)                                                               | 0.01  |
|                                                                        | 42 (27.8)                                                                | 71 (45.5)                                                                  |       |
|                                                                        | 31 (33)                                                                  | 42 (45)                                                                    |       |
|                                                                        | In-hospital mortality, n (%)                                              | In-hospital mortality, n (%)                                               | 0.07  |
|                                                                        | 61 (40.4)                                                                | 102 (65.4)                                                                 |       |
|                                                                        | 40 (43)                                                                  | 59 (63)                                                                    |       |
|                                                                        | Hospital length of stay, median (IQR)                                    | Hospital length of stay, median (IQR)                                    | 0.03  |
|                                                                        | 18.0 (11.0–26.0)                                                         | 16.0 (11.0–22.0)                                                           |       |
|                                                                        | 18.0 (13.0–24.0)                                                         | 15.0 (10.0–18.0)                                                           |       |

DCCB = dihydropyridine calcium channel blockers.  
Dashes indicate that this item is not compared.  
*p < 0.05.

mmol/L (HR, 1.454; 95% CI, 1.041–2.029; p = 0.028). Kaplan–Meier analysis showed that in patients without PSM who treated with DCCB had a significant worse mortality (Fig. 1A) (log-rank p < 0.0001).

**Characteristics of Hypertensive Patients With or Without DCCB Was Reported When Moderate-Severe ARDS Induced by Pulmonary Occurred After PSM**

In group with PSM, in-hospital mortality was significantly higher in patients treated with DCCB than in those without DCCB (65.4% vs 40.4%; p < 0.01). Kaplan–Meier analysis showed that patients not treated with DCCB had a significant survival advantage over those treated with DCCB in patients with PSM (Fig. 1B) (log-rank p = 0.001).

In this patient population after PSM, the median age was 75.0 years (IQR, 67.0–80.0 yr), and 79.6% (148/186) were male. 46.8% of patients (87/186) had a history of alcohol consumption. The most commonly reported comorbidities were diabetes mellitus, 24.7% (46/186), and coronary artery disease, 19.9% (37/186). Of the 186 patients, 159 (85.5%) were in hypertension grade I. The proportion of patients with hypertension grade II was 14.5%. In our study, 53.2% of patients (99/186) died during hospitalization. The median length of hospital stay was 16 days (IQR, 12.0–23.0 d) (Table S1, http://links.lww.com/CCX/A749).

There were no differences in age, history of smoking consumption, hemoglobin, albumin, LDH, or Pao\_2/Fio\_2 ratio between patients with or without DCCB. Of the 93 patients with a history of chronic DCCB, 79 (85%) were in hypertension grade I, and 14 (15%) were grade II. Among patients treated with DCCB, a lower proportion of patients had the history of alcohol consumption than those who were not treated with DCCB (43 vs 44; p = 0.02). Patients treated with DCCB had a larger population of severe ARDS (30 vs 28; p = 0.03) and significantly higher SOFA score (p = 0.05). However, there was no significant difference in APACHE II score between these two groups (p = 0.67). Also, there was no significant difference in mechanical ventilation between DCCB and non-DCCB patients (p = 1.0) (Table 1).
### TABLE 2.
Comparison of Demographics and Clinicopathologic Characteristics of Unmatched and Matched Hospitalized Acute Respiratory Distress Syndrome Patients With Hypertension in Different Prognosis

| Factors                                      | Pre Matched | Post Matched |
|----------------------------------------------|-------------|--------------|
|                                              | Survivor \(N = 144\) | NonSurvivor \(N = 163\) | \(p\) | Survivor \(N = 87\) | NonSurvivor \(N = 99\) | \(p\) |
| Male, %, \(n (\%)\)                         | 99 (68.8)   | 137 (84.0)   | < 0.01 | 67 (77)   | 81 (82)   | 0.42 |
| Age, median (interquartile ranges)           | 75.0 (66.0–82.0) | 73.0 (66.0–79.0) | 0.38 | 75.0 (67.0–79.0) | 75.0 (66.0–83.0) | 0.53 |
| Smoke, \(n (\%)\)                           | 92 (63.9)   | 96 (58.9)    | 0.37 | 56 (64)    | 63 (64)    | 0.92 |
| Alcohol, \(n (\%)\)                         | 58 (40.3)   | 75 (46.0)    | 0.31 | 39 (45)    | 48 (48)    | 0.62 |
| With dihydropyridine calcium channel blocker, \(n (\%)\) | 54 (37.5)  | 102 (62.6)   | < 0.01\(^a\) | 34 (39)  | 59 (60)   | < 0.01\(^a\) |
| Hypertension grade, \(n (\%)\)              |             |              | 0.73 |             | 0.79 |       |
| I                                            | 118 (81.9)  | 136 (83.4)   | –   | 75 (86)    | 84 (85)    | –    |
| II                                           | 26 (18.1)   | 27 (16.6)    | –   | 12 (14)    | 15 (15)    | –    |
| Pre-existing comorbidity, \(n (\%)\)        |             |              | 0.21 |             | 0.80 |       |
| Coronary artery disease                      | 33 (22.9)   | 28 (17.2)    | –   | 18 (21)    | 19 (19)    | –    |
| Diabetes mellitus                            | 47 (32.6)   | 34 (20.9)    | 0.02\(^a\) | 28 (32)  | 18 (18)    | 0.03\(^a\) |
| Laboratory findings                          |             |              | 0.13 |             | 0.72 |       |
| Pao/Fio\(_2\) ratio, median (interquartile ranges) | 120.0 (97.0–166.0) | 117.3 (88.0–145.0) | 0.04\(^a\) | 115.0 (90.0–161.0) | 128.0 (92.0–170.0) | 0.87 |
| Categories of acute respiratory distress syndrome, \(n (\%)\) |             |              | 0.13 |             | 0.72 |       |
| Moderate                                     | 101 (70.1)  | 101 (62.0)   | –   | 61 (70)    | 67 (68)    | –    |
| Severe                                       | 43 (29.9)   | 62 (38.0)    | –   | 26 (30)    | 32 (32)    | –    |
| WBC, median (interquartile ranges)           | 9.7 (7.9–13.0) | 9.7 (6.9–13.0) | 0.72 | 9.6 (8.0–14.2) | 9.7 (8.8–13.0) | 0.70 |
| Hemoglobin, median (interquartile ranges)    | 115.0 (96.0–131.0) | 107.0 (91.0–121.0) | 0.04\(^a\) | 109.0 (96.0–130.0) | 103.0 (89.0–115.0) | < 0.01\(^a\) |
| Platelets, median (interquartile ranges)     | 151.0 (106.0–196.0) | 130.0 (67.0–187.0) | < 0.01\(^a\) | 180.0 (109.0–208.0) | 136.0 (98.0–198.0) | 0.06 |
| Albumin, median (interquartile ranges)       | 32.1 (30.0–35.0) | 30.0 (25.9–34.0) | < 0.01\(^a\) | 32.1 (30.0–35.0) | 30.0 (23.6–34.0) | < 0.01\(^a\) |
| Creatinine, median (interquartile ranges)    | 77.0 (60.0–112.0) | 91.0 (55.0–121.0) | 0.49 | 86.0 (60.0–123.2) | 91.9 (54.0–113.1) | 0.95 |
| Blood urea nitrogen, median (interquartile ranges) | 11.2 (8.0–16.6) | 11.0 (8.4–17.5) | 0.05 | 11.7 (8.0–15.4) | 11.0 (8.7–17.5) | 0.06 |
| Lactate dehydrogenase, median (interquartile ranges) | 308.0 (226.5–419.0) | 381.0 (271.0–630.0) | < 0.01\(^a\) | 321.0 (188.8–419.0) | 444.0 (280.0–630.0) | < 0.01\(^a\) |
| Lactate, median (interquartile ranges)       | 1.9 (1.3–2.5) | 2.2 (1.6–2.9) | 0.01\(^a\) | 1.8 (1.2–2.5) | 2.1 (1.8–2.8) | 0.01\(^a\) |
| C-reactive protein, median (interquartile ranges) | 105.0 (43.5–175.5) | 95.6 (33.6–154.0) | 0.22 | 109.0 (35.0–195.0) | 109.0 (35.0–154.0) | 0.84 |
| Procalcitonin                                | 0.8 (0.3–2.1) | 1.6 (0.3–5.7) | 0.02\(^a\) | 0.6 (0.3–1.6) | 0.9 (0.3–5.7) | 0.04\(^a\) |

(Continued)
TABLE 2. (Continued).
Comparison of Demographics and Clinicopathologic Characteristics of Unmatched and Matched Hospitalized Acute Respiratory Distress Syndrome Patients With Hypertension in Different Prognosis

| Factors                                                                 | Pre Matched                     | Post Matched                      |
|------------------------------------------------------------------------|---------------------------------|-----------------------------------|
|                                                                        | Survivor (N = 144) | Nonsurvivor (N = 163) | p    | Survivor (N = 87) | Nonsurvivor (N = 99) | p    |
| Acute Physiology and Chronic Health Evaluation II score, median         | 8.5 (6.0–12.5) | 10.0 (7.0–12.0) | 0.06 | 8.0 (6.0–14.0) | 9.0 (7.0–12.0) | 0.49 |
| (interquartile ranges)                                                 |                                |                                |      |                  |                    |
| Sequential Organ Failure Assessment score, median                      | 3.0 (2.0–4.0) | 3.0 (2.0–4.5) | 0.47 | 2.0 (2.0–4.0) | 3.0 (2.0–6.0) | 0.16 |
| (interquartile ranges)                                                 |                                |                                |      |                  |                    |

Outcomes

| Outcomes                                      | Pre Matched | Post Matched |
|-----------------------------------------------|-------------|--------------|
| Mechanical ventilation, n (%)                | 107 (74.3)  | 64 (74)      |
| (N = 144)                                    | 138 (84.7)  | 84 (85)      |
| Shock, n (%)                                 | 36 (25.0)   | 26 (30)      |
| (N = 144)                                    | 77 (47.2)   | 47 (47)      |
| Hospital length of stay, median (interquartile ranges) | 18.0 (13.0–24.0) | 18.0 (13.0–24.0) |
| (N = 144)                                    | 16.0 (10.0–22.0) | 15.0 (10.0–18.0) |

Dashes indicate that this item is not compared.

\*p < 0.05.

By multivariate Cox regression analysis, factors associated with an increased risk of patient death during hospitalization included DCCB (HR, 2.021; 95% CI, 1.333–3.064; \( p = 0.001 \)), LDH greater than or equal to 600 U/L (HR, 4.379; 95% CI, 2.642–7.257; \( p < 0.001 \)), and lactate greater than or equal to 2 mmol/L (HR, 2.461; 95% CI, 1.534–3.951; \( p < 0.001 \)).

DISCUSSION

In this multicenter retrospective survey, DCCB, LDH greater than or equal to 600 U/L, and lactate greater than or equal to 2 mmol/L at admission were significantly associated with an increased risk of death during hospitalization in hypertensive patients who developed moderate-severe pulmonary ARDS.

Investigation of our group showed that DCCB could induce up-regulation of expression and functional activation of the CaSR in PASMC, which leads to the release of calcium from the sarcoplasmic reticulum and facilitates the flow of extracellular calcium, together contributing to an increase in intracellular calcium concentration (24–26). This may lead to increased PASMC proliferation, pulmonary vascular permeability, pulmonary fibrosis, and worsen pulmonary hypertension, which could increase mortality in ARDS (27).

TABLE 3.
Multivariate Cox Regression Analysis of Risk Factors for Mortality of Moderate-Severe Direct Acute Respiratory Distress Syndrome Patients With Hypertension

| Factors                                      | Pre Matched | Post Matched |
|----------------------------------------------|-------------|--------------|
| With dihydropyridine calcium channel blocker | 1.954 (1.415–2.699) | 2.021 (1.333–3.064) |
| HR (95% CI)                                  | \( < 0.001 \) | \( p = 0.001 \) |
| Lactate dehydrogenase\* ≥ 600                | 3.089 (2.106–4.531) | 4.379 (2.64–7.257) |
| HR (95% CI)                                  | \( < 0.001 \) | \( < 0.001 \) |
| Lactate\* ≥ 2 mmol/L                        | 1.454 (1.041–2.029) | 2.461 (1.534–3.951) |
| HR (95% CI)                                  | 0.028       | \( < 0.001 \) |

\*Laboratory finding upon admission.

HR = hazard ratio.
Pulmonary artery endothelial cells migration and proliferation could cause pulmonary vascular obstruction in mitochondrial Ca\(^{2+}\)-dependent manner when calcium increases in the cell (26). The increased intracellular Ca\(^{2+}\) could induce the apoptosis of type II pneumocytes as well, mediating ARDS-related lung injury (8). These results may explain pulmonary vasocostriction and reconstitution could improve the mortality rate of patients with pulmonary hypertension in ARDS (6, 12, 28).

Serum lactate has been clinically considered as a marker of tissue hypoxia and is often used as a biological indicator of prognosis (29). Blood lactate is produced by RBCs, brain tissue, and striated muscle. The blood lactate level mainly depends on the synthesis and metabolism speed of the liver and kidneys. Under pathologic conditions, critical illnesses such as respiratory failure or circulatory failure could lead to tissue hypoxia and increased lactate production (30). Thus, the lactic acid level may reflect the severity of the disease to a certain extent. Reports had shown that lung lactate production might become clinically evident in disease states especially in the patients with ARDS (31). Study had also found that lactate has an immunosuppressive effect and played an important role in immune regulation and inflammatory response (32). In our investigation, we also learned that LDH greater than or equal to 600 U/L is a risk factor for hypertension in patients with ARDS. There were reports showed that higher LDH level could be a predictor of prognosis in patients with ARDS (33, 34). LDH could be released from cells when there was damage to the cytoplasmic membrane. It is not only a metabolic but also an immune surveillance prognostic biomarker (35). LDH could represent an expression of lung damage consequent to the inflammation status. Elevated LDH values have been found in other interstitial lung infections (36).

Some limitations of the present study are worth mentioning. First, this is a retrospective study. Although this multicenter study may be representative, our epidemiology cannot be extrapolated to all settings. PSM could eliminate bias or control confounding, as it may also exacerbate some forms or such forms of bias. In addition, there were many factors that could cause bias that we did not include. Patients’ different socioeconomic status might also be a source of deviation. Second, mechanical ventilation strategies are strictly in accordance with the guidelines; there is heterogeneity in organ support therapy due to some patients’ lack of invasive hemodynamic monitoring. This may have introduced bias favoring benefit from treatment measures. Finally, pulmonary

![Figure 1. Kaplan-Meier survival curves for mortality during hospitalization. The numbers below the figure represent the number of inpatients at risk of death on a given date who had or did not have the history of dihydropyridine calcium channel blocker (DCCB). A, Kaplan-Meier survival curves of mortality for unmatched inpatients. B, Kaplan-Meier survival curves of mortality for matched inpatients.](image)
arterial hypertension (PAH) World Health Organization (WHO) Group 1 and Group 3 are different diseases and have different pathogenic mechanisms. Our prior works were focused on the PASMC from both idiopathic PAH patients and hypoxic pulmonary hypertension (HPH) HPH mice. As the PAH in ARDS patients belongs to WHO Group 3, we make the assumption that CCB may have similar work in HPH mice and in ARDS patients. However, the pathogenesis of ARDS is still unclear; the pathogenesis of ARDS patients with hypertension is much more complex. The mechanism of DCCB affecting the prognosis of patients with hypertension and ARDS needs further study. And, all patients enrolled in the study were given medication for more than 3 months, but the specific duration of medication is still unclear. Our study only provides a clinical clue. Hopefully, our study will provoke some randomized clinical trial researches and basic experiments to further elucidate the effect of DCCB on hypertension combined with ARDS.

CONCLUSIONS

The results of this study provide insight into the effect of DCCB on mortality in patients with hypertension and moderate-severe pulmonary ARDS, with DCCB, LDH greater than or equal to 600 U/L, and lactate greater than or equal to 2 mmol/L at admission being independent risk factors for mortality. Further studies are needed to reveal the effect of DCCB on hypertension combined with moderate-severe pulmonary ARDS.

ACKNOWLEDGMENTS

We thank Lijuan Yang, Ying He, and Feng Yao for their devotion in collecting data. We also thank all staff in medical information department of hospitals for their help in data management.

REFERENCES

1. Yadav H, Thompson BT, Gajic O: Fifty years of research in ARDS. Is acute respiratory distress syndrome a preventable disease? Am J Respir Crit Care Med 2017; 195:725–736
2. Seeliger B, Stahl K, Schenk H, et al: Extracorporeal membrane oxygenation for severe ARDS due to immune diffuse alveolar hemorrhage: A retrospective observational study. Chest 2020; 157:744–747
3. Abrams D, Schmidt M, Pham T, et al: Mechanical ventilation for acute respiratory distress syndrome during extracorporeal life support. Research and practice. Am J Respir Crit Care Med 2020; 201:514–525
4. Ryan D, Frohlich S, McLoughlin P: Pulmonary vascular dysfunction in ARDS. Ann Intensive Care 2014; 4:28
5. Lai PS, Mita C, Thompson BT: What is the clinical significance of pulmonary hypertension in acute respiratory distress syndrome? A review. Minerva Anestesiol 2014; 80:574–585
6. Yamamura A, Guo Q, Yamamura H, et al: Enhanced Ca(2+)-sensing receptor function in idiopathic pulmonary arterial hypertension. Circ Res 2012; 111:469–481
7. Yamamura A, Yamamura H, Guo Q, et al: Dihydropyridine Ca(2+) channel blockers increase cytosolic [Ca(2+)] by activating Ca(2+)-sensing receptors in pulmonary arterial smooth muscle cells. Circ Res 2013; 112:640–650
8. Zhang K, Wang P, Huang S, et al: Different mechanism of LPS-induced calcium increase in human lung epithelial cell and microvascular endothelial cell: A cell culture study in a model for ARDS. Mol Biol Rep 2014; 41:4253–4259
9. Pandolfi R, Barreira B, Moreno E, et al: Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction. Thorax 2017; 72:460–471
10. Medarov BI, Judson MA: The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today? Respir Med 2015; 109:557–564
11. Yamamura A: Molecular mechanism of dihydropyridine Ca\(^{2+}\) channel blockers in pulmonary hypertension. Yakugaku Zasshi 2016; 136:1373–1377
12. Yamamura A: Pathological function of Ca\(^{2+}\)-sensing receptor in pulmonary arterial hypertension. J Smooth Muscle Res 2014; 50:8–17
13. Shields DL: Calcium channel blockers as initial therapeutic agents in hypertension: Relationship to incident heart failure. Biol Res Nurs 2014; 16:266–277
14. Aung K: ACP Journal Club. Review: Adding an ACE inhibitor or ARB to CCB therapy reduces CCB-associated edema in patients with hypertension. Ann Intern Med 2011; 155:JC1–J11
15. Cuschieri J, Gourlay D, Garcia I, et al: Slow channel calcium inhibition blocks proinflammatory gene signaling and reduces macrophage responsiveness. J Trauma 2002; 52:434–442
16. Ranieri VM, Rubenfeld GD, Thompson BT, et al; ARDS Definition Task Force: Acute respiratory distress syndrome: The Berlin definition. JAMA 2012; 307:2526–2533
17. Fan E, Brodie D, Slutsky AS: Acute respiratory distress syndrome: Advances in diagnosis and treatment. JAMA 2018; 319:698–710
18. Unger T, Borghi C, Charchar F, et al: 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens 2020; 38:982–1004
19. Borzecchi AM, Kader B, Berlowitz DR: The epidemiology and management of severe hypertension. J Hum Hypertens 2010; 24:9–18
20. Slutsky AS: History of mechanical ventilation. From vesalius to ventilator-induced lung injury. Am J Respir Crit Care Med 2015; 191:1106–1115
21. Yoshida T, Fujino Y, Amato MB, et al: Fifty years of research in ARDS. Spontaneous breathing during mechanical ventilation. risks, mechanisms, and management. Am J Respir Crit Care Med 2017; 195:985–992
22. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818–829
23. Raith EP, Udy AA, Bailey M, et al; Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes and Resource Evaluation (CORE): Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA 2017; 317:290–300
24. Guo Q, Xu H, Yang X, et al: Notch activation of Ca\(^{2+}\)-sensing receptor mediates hypoxia-induced pulmonary hypertension. Hypertens Res 2017; 40:117–129
25. Smith KA, Voiriot G, Tang H, et al: Notch activation of Ca\(^{2+}\) signaling in the development of hypoxic pulmonary vasoconstriction and pulmonary hypertension. Am J Respir Cell Mol Biol 2015; 53:355–367
26. Shen T, Wang N, Yu X, et al: The critical role of dynamin-related protein 1 in hypoxia-induced pulmonary vascular angiogenesis. J Cell Biochem 2015; 116:1993–2007
27. Cardinal-Fernández P, Lorente JA, Ballén-Barragán A, et al: Acute respiratory distress syndrome and diffuse alveolar damage. New insights on a complex relationship. Ann Am Thorac Soc 2017; 14:844–850
28. Smith KA, Ayon RJ, Tang H, et al: Calcium-sensing receptor regulates cytosolic [Ca\(^{2+}\)] and plays a major role in the development of pulmonary hypertension. Front Physiol 2016; 7:517
29. Kamo T, Tasaka S, Suzuki T, et al: Prognostic values of the Berlin definition criteria, blood lactate level, and fibroproliferative changes on high-resolution computed tomography in ARDS patients. BMC Pulm Med 2019; 19:37
30. Bakker J, Nijsten MW, Jansen TC: Clinical use of lactate monitoring in critically ill patients. Ann Intensive Care 2013; 3:12
31. Iscra F, Gullo A, Biolo G: Bench-to-bedside review: Lactate and the lung. Crit Care 2002; 6:327–329
32. Nolt B, Tu F, Wang X, et al: Lactate and immunosuppression in sepsis. Shock 2018; 49:120–125
33. Xu B, Ge Y, Lu Y, et al: Risk factors and prognosis of acute respiratory distress syndrome following abdominal surgery. Exp Ther Med 2019; 17:159–164
34. Chen CY, Lee CH, Liu CY, et al: Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome. J Chin Med Assoc 2005; 68:4–10
35. Kuang ZS, Yang YL, Wei W, et al: Clinical characteristics and prognosis of community-acquired pneumonia in autoimmune disease-induced immunocompromised host: A retrospective observational study. World J Emerg Med 2020; 11:145–151
36. Poggiali E, Zaino D, Immovilli P, et al: Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in COVID-19 patients. Clin Chim Acta 2020; 509:135–138